Laryngeal Carcinoma in Patients With Inflammatory Bowel Disease: Clinical Outcomes and Risk Factors

被引:5
|
作者
van de Ven, Steffi E. M. [1 ]
Derikx, Lauranne A. A. P. [2 ]
Nagtegaal, Iris D. [3 ]
van Herpen, Carla M. [4 ]
Takes, Robert P. [5 ]
Melchers, Willem J. G. [6 ]
Pierik, Marieke [7 ]
van den Heuvel, Tim [7 ]
Verhoeven, Rob H. A. [8 ]
Hoentjen, Frank [2 ]
Nissen, L. H. C. [9 ]
机构
[1] Erasmus MC, Univ Med Ctr, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Dept Gastroenterol & Hepatol, Nijmegen, Netherlands
[3] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, Nijmegen, Netherlands
[4] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, Nijmegen, Netherlands
[5] Radboud Univ Nijmegen, Med Ctr, Dept Otolaryngol & Head & Neck Surg, Nijmegen, Netherlands
[6] Radboud Univ Nijmegen, Med Ctr, Dept Med Microbiol, Nijmegen, Netherlands
[7] Maastricht Univ, Med Ctr, Dept Gastroenterol & Hepatol, Maastricht, Netherlands
[8] Netherlands Comprehens Canc Org, Dept Res & Dev, Utrecht, Netherlands
[9] Jeroen Bosch Hosp, Dept Gastroenterol & Hepatol, Henri Dunantstr 1,Postbox 90153, NL-5200 ME Shertogenbosch, Netherlands
关键词
inflammatory bowel diseases; head and neck cancer; laryngeal carcinoma; immunosuppressive therapy; SQUAMOUS-CELL CARCINOMA; LIVER-TRANSPLANTATION; COLORECTAL-CANCER; CROHNS-DISEASE; ULCERATIVE-COLITIS; NECK-CANCER; NATIONWIDE; NEOPLASIA; HEAD; MALIGNANCY;
D O I
10.1093/ibd/izz210
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Inflammatory bowel disease (IBD) patients are at increased risk for developing extra-intestinal malignancies, mainly due to immunosuppressive medication. The risk of developing head and neck cancer in immunosuppressed transplant patients is increased. The relation between IBD patients and laryngeal cancer (LC) remains unclear. We aimed (1) to identify risk factors in IBD patients for LC development and (2) to compare clinical characteristics, outcome, and survival of LC in IBD patients with the general population. Methods: All IBD patients with LC (1993-2011) were retrospectively identified using the Dutch Pathology Database. We performed 2 casecontrol studies: (1) to identify risk factors, we compared patients with IBD and LC (cases) with the general IBD population; (2) to analyze LC survival, we compared cases with controls from the general LC population. Results: We included 55 cases, 1800 IBD controls, and 2018 LC controls. Cases were more frequently male compared with IBD controls (P < 0.001). For ulcerative colitis (UC), cases were older at IBD diagnosis (P < 0.001). Crohn's disease (CD) cases were more frequently tobacco users (P < 0.001) and more often had stricturing (P = 0.006) and penetrating (P = 0.008) disease. We found no survival difference. Immunosuppressive medication had no impact on survival. Conclusions: Male sex was a risk factor for LC in IBD patients. Older age at IBD diagnosis was a risk factor for UC to develop LC. Tobacco use and stricturing and penetrating disease were risk factors for LC development in CD patients. Inflammatory bowel disease was not associated with impaired survival of LC. Immunosuppressive medication had no influence on survival.
引用
收藏
页码:1060 / 1067
页数:8
相关论文
共 50 条
  • [1] Clinical assessment of risk factors for infection in inflammatory bowel disease patients
    Tosca, Joan
    Garcia, Natalia
    Pascual, Isabel
    Bosca-Watts, Marta Maia
    Anton, Rosario
    Sanahuja, Ana
    Mas, Pilar
    Mora, Francisco
    Minguez, Miguel
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2020, 35 (03) : 491 - 500
  • [2] Clinical assessment of risk factors for infection in inflammatory bowel disease patients
    Joan Tosca
    Natalia Garcia
    Isabel Pascual
    Marta Maia Bosca-Watts
    Rosario Anton
    Ana Sanahuja
    Pilar Mas
    Francisco Mora
    Miguel Minguez
    International Journal of Colorectal Disease, 2020, 35 : 491 - 500
  • [3] Prevalence, risk factors and clinical outcomes of malignancies in patients with Inflammatory Bowel Disease: a case-control study
    Foteinogiannopoulou, K.
    Nikolaou, P.
    Orfanoudaki, E.
    Theodoraki, E.
    Theodoropoulou, A.
    Karmiris, K.
    Koutroubakis, I
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i856 - i858
  • [4] Risk Factors for Adverse Pregnancy Outcomes in Inflammatory Bowel Disease
    Garrido, Isabel
    Santos, Ana Luisa
    Lopes, Susana
    Macedo, Guilherme
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S359 - S359
  • [5] OSTEOPOROSIS RISK FACTORS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Nassar, K.
    Janani, S.
    OSTEOPOROSIS INTERNATIONAL, 2021, 32 (SUPPL 1) : S148 - S149
  • [6] Novel risk factors and outcomes in inflammatory bowel disease patients with Clostridioides difficile infection
    Voth, Elida
    Solanky, Dipesh
    Loftus, Edward V., Jr.
    Pardi, Darrell S.
    Khanna, Sahil
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2021, 14
  • [7] Thrombophilic Risk Factors in Patients With Inflammatory Bowel Disease
    Yazici, Ayten
    Senturk, Omer
    Aygun, Cem
    Celebi, Altay
    Caglayan, Cigdem
    Hulagu, Sadettin
    GASTROENTEROLOGY RESEARCH, 2010, 3 (03) : 112 - 119
  • [8] Novel Risk Factors and Outcomes in Inflammatory Bowel Disease Patients With Clostridium difficile Infection
    Voth, Elida
    Solanky, Dipesh
    Loftus, Edward V., Jr.
    Pardi, Darrell
    Khanna, Sahil
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S442 - S442
  • [9] NOVEL RISK FACTORS AND OUTCOMES IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH CLOSTRIDIUM DIFFICILE INFECTION
    Voth, Elida
    Solanky, Dipesh
    Loftus, Edward V.
    Pardi, Darrell S.
    Khanna, Sahil
    GASTROENTEROLOGY, 2019, 156 (03) : S50 - S50
  • [10] Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease
    Wang, Jingzhou
    Prenner, Joshua
    Wang, Wenfei
    Sakuraba, Atsushi
    Hyman, Neil
    Dalal, Sushila
    Hurst, Roger
    Cohen, Russell D.
    Umanskiy, Konstantin
    Shogan, Benjamin D.
    Alpert, Lindsay
    Rubin, David T.
    Colwell, Janice
    Pekow, Joel
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 51 (12) : 1365 - 1372